根据中国证监会《上市公司独立董事规则》《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》及《公司章程》等法律法规的有关 规定，我们作为德展大健康股份有限公司独立董事，就公司第八届董事会第十七 次会议聘任的常务副总经理、副总经理和首席科学家发表以下独立意见： 德展大健康股份有限公司 独立董事关于聘任公司常务副总经理、副总经理和首席科学家的 独立意见 （此页无正文，为公司独立董事关于聘任公司常务副总经理、副总经理和首席科 学家的独立意见签字页） 独立董事签字： 王新安 孙卫红 武 滨____________ 二〇二三年八月二十一日 经审阅张婧红女士、王曙宾先生、刘晔先生的个人履历等相关资料，我们认 为张婧红女士、王曙宾先生、刘晔先生具备相关专业知识和技能，任职资格符合 《公司法》和《公司章程》等有关规定。未发现有《公司法》规定的不得担任公 司高级管理人员等职务的情况，以及被中国证监会认定为市场禁入者或者禁入尚 未解除的情况。其选聘和提名程序符合《公司法》和《公司章程》的有关规定， 不存在损害公司及其股东利益的情况，其任职资格合法；我们同意聘任张婧红女 士为公司常务副总经理兼财务总监，王曙宾 ...

证券代码：000813 证券简称：德展健康 公告编号：2023-053 德展大健康股份有限公司 关于持股 5%以上股东股份被动减持股份暨 后续减持计划的预披露公告 美林控股集团有限公司保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、美林控股在华福证券开展的质押式回购业务发生违约，华福证券通过集中 竞价方式对美林控股所持本公司 21,649,500 股股份进行强制卖出。 德展大健康股份有限公司（以下简称"德展健康"、"公司"或"本公司"） 于近日收到公司持股 5%以上股东美林控股集团有限公司（以下简称"美林控股"） 《关于美林控股被动减持股份暨后续减持计划告知函》，获悉美林控股所持本公 司 21,649,500 股股份发生被动减持，同时美林控股计划在未来三个月内以集中竞 价或大宗交易主动或被动减持本公司股份 21,734,809 股（含上述已减持 21,649,500 股股份，尚余 85,309 股股份未减持），即减持股份数量不超过公司总 股本的 1%。现将有关情况公告如下： 一、本次被动减持 ...

证券代码：000813 证券简称：德展健康 编号：2023-001 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他（请文字说明其他活动内容） 活动参与人员 保宁资本：黄静 时间 2023 年 6 月 28 日下午 地点 北京市朝阳区工体东路乙 2 号美林大厦 10 层公司会议室 形式 现场调研 上市公司接待 人员姓名 副总经理、董事会秘书：肖建峰；证券部：李萍 问题一、集采对于公司产品而言有何影响？ 答：近年来受集采政策影响，公司核心产品阿乐总体销量及销售收 入有所下滑，对公司总体营业收入构成一定影响。就公司目前业务 而言，阿乐仍然是公司的核心产品，未来尼乐作为新增重要品种， 将为公司巩固血脂调节剂市场形成补充。 交流内容及具 问题二、因为尼乐今年进入集采，所以销量会放大吗？ 体问答记录 答：尼乐今年 4 月份中标集采，确定了尼乐主供的区域包括河北、 山西、黑龙江、上海、安徽、四川、贵州等省份。尼乐（氨氯地平 阿托伐他汀钙片）2021 年 6 月收到国家药监局核准签发的《药品注 册证书》，成为首个获批的复方降压降脂国产药品。公司正在按 ...

证券代码：000813 证券简称：德展健康 公告编号：2023-036 德展大健康股份有限公司 关于参加新疆辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，德展大健康股份有限公司（以下简称"公 司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有限公司联合 举办的"2023 年新疆辖区上市公司投资者集体接待日活动"，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）10:30-18:00，届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告！ 德展大健康股份有限公司董事会 二〇二三年六月十日 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a growth of 15% compared to the previous year[13]. - The company's operating revenue for 2022 was ¥570,855,435.18, a decrease of 22.28% compared to ¥734,479,885.95 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥46,908,665.33, an improvement of 18.54% from -¥57,581,886.98 in 2021[19]. - The total revenue for 2022 was CNY 570.86 million, a decrease of 22.28% compared to the previous year[54]. - The pharmaceutical sector generated CNY 562.19 million in revenue, representing 98.48% of total revenue and a decline of 20.05% year-on-year[56]. - The company reported a significant increase in cash flow from operations, indicating potential for improved liquidity and operational efficiency moving forward[19]. - The company achieved a net increase in cash and cash equivalents of ¥1,122,599,535.77 in 2022, a significant improvement from a decrease of ¥349,738,061.95 in 2021, reflecting a 420.98% change[71]. - The company reported a total investment of 91,611.08 million CNY for various projects, achieving 100% of the planned investment[86]. User Growth and Market Expansion - User data showed a rise in active users, reaching 5 million, which is an increase of 20% year-on-year[13]. - The company has set a future outlook with a revenue target of 1.5 billion RMB for 2023, indicating a projected growth of 25%[13]. - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in these regions[13]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[132]. - The company plans to enhance its digital platform, aiming for a 40% increase in online sales channels[132]. Research and Development - The company plans to invest 100 million RMB in R&D for new technologies over the next year[13]. - The company has established four specialized pharmaceutical research institutions with approximately 200 experienced R&D personnel, focusing on technological innovation and new drug development[43]. - The company has over 200 R&D personnel working on more than 20 projects, including several innovative drug candidates[50]. - The company is in the preclinical research phase for a new innovative drug targeting acute ischemic stroke, aiming for IND submission in approximately 1.5 years[67]. - The company has made progress in developing CBD-based treatments for rare diseases, with patent grants in major global markets[67]. - The company plans to accelerate the progress of R&D projects in 2023, with specific targets including entering clinical stages for the WYY project and ZT project, and achieving production approval for Trimetazidine Hydrochloride Tablets[100]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local health tech firm was completed, valued at 300 million RMB, to enhance technological capabilities[13]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[127]. - The company has established partnerships with two major distributors to enhance its supply chain efficiency[127]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency by reducing costs by 5% through process optimization initiatives[13]. - The company is actively pursuing cost reduction strategies, resulting in significant decreases in raw material costs[52]. - The company will implement cost reduction and efficiency enhancement strategies in 2023, aiming to improve capacity utilization and reduce unit costs through better supplier management and production technology innovation[101]. Risk Management - The management has identified potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[3]. - The company faces risks from market and policy changes, particularly due to the ongoing reforms in the pharmaceutical industry and stricter regulations[103]. - The company will manage production cost risks by establishing long-term partnerships with quality suppliers and innovating production processes[104]. Governance and Compliance - The company maintains complete operational independence from its controlling shareholder, Kaidi Investment, in terms of business, personnel, assets, and finance[112]. - The company has established a comprehensive financial management system, with independent accounting practices and tax obligations, ensuring no interference from the controlling shareholder[113]. - The company has a complete governance structure, with independent directors holding a majority in key committees, ensuring fair treatment of all shareholders[111]. - The company is committed to improving its governance structure by appointing qualified individuals to its board and management team[120]. Environmental Responsibility - The company has achieved compliance with national standards for pollution discharge in its production activities, with specific pollutant discharge limits outlined[172]. - The company has completed environmental impact report approvals for multiple projects, including the high Qing production base and Huan Tai medical beauty project[172]. - The company achieved a 100% compliance rate for wastewater discharge, meeting both Beijing and local sewage discharge standards[181]. - JiaLin Pharmaceutical invested approximately 2.01 million yuan in environmental governance and protection in 2022[180]. Shareholder Relations and Profit Distribution - No cash dividends will be distributed to shareholders for the fiscal year 2022, as the company focuses on reinvestment[4]. - The company reported a net profit attributable to shareholders of -46,908,665.33 CNY for 2022, with an initial undistributed profit of 3,894,471,040.61 CNY[151]. - The profit distribution plan for 2022 was deemed reasonable and compliant with relevant regulations, ensuring the protection of minority shareholders' interests[153]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,082, with 30 in the parent company and 1,052 in major subsidiaries[147]. - The company has implemented various training programs, including professional skills training and safety management, targeting different employee groups[150]. - The company emphasizes the importance of adjusting the shareholding structure before project initiation to prevent external shareholders from influencing future investments[146].

Financial Performance - The company's revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.90% compared to ¥192,816,625.91 in the same period last year[5] - Net profit attributable to shareholders was ¥1,859,373.76, down 93.89% from ¥30,445,095.31 year-on-year[5] - The net cash flow from operating activities was ¥49,861,633.81, a decline of 61.77% compared to ¥130,435,562.96 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0008, representing a decrease of 94.12% from ¥0.0136 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.9% compared to ¥192,816,625.91 in the same period last year[22] - Net profit for Q1 2023 was ¥582,608.11, a significant decline from ¥22,929,114.75 in Q1 2022, representing a decrease of 97.5%[24] - Total comprehensive income for the period amounted to CNY 582,608.11, a decrease from CNY 22,929,114.75 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,554,524,795.94, down 2.11% from ¥5,674,395,997.63 at the end of the previous year[5] - Total assets decreased to ¥5,554,524,795.94 from ¥5,674,395,997.63, a reduction of 2.1%[21] - Total liabilities decreased to ¥328,445,794.71 from ¥390,381,648.39, a decline of 15.9%[21] Cash Flow - The company's cash and cash equivalents increased to ¥2,985,284,796.13 from ¥2,599,135,458.30 at the beginning of the year, reflecting a growth of 14.8%[20] - Cash inflow from investment activities reached CNY 400,005,200.00, significantly higher than CNY 80,551,396.03 in the previous period, indicating a growth of 396.5%[27] - Net cash flow from investment activities was CNY 386,383,653.20, compared to a negative CNY 15,445,078.29 in the previous period, showing a substantial turnaround[27] - Total cash inflow from operating activities was CNY 187,407,681.48, down from CNY 299,649,594.13 in the previous period, a decline of about 37.4%[26] - Total cash outflow from operating activities was CNY 137,546,047.67, compared to CNY 169,214,031.17 in the previous period, a decrease of approximately 18.7%[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,330[12] - Major shareholders include Meilin Holdings Group with 19.11% and Shanghai Yueye Equity Investment Management with 18.60%[13] - The company’s major shareholder, Meilin Holdings, holds 425,470,400 shares, representing 19.11% of the total share capital[17] - The company’s top ten shareholders include significant stakes from Xinjiang Kaidi Investment and Xinjiang Kaidi Mining, with holdings of 409,748,445 shares and 104,039,367 shares respectively[14] - The company’s top ten shareholders have a combined holding of 1.17% in the repurchase special account[15] Share Repurchase - As of March 31, 2023, the company repurchased a total of 26,105,140 shares, accounting for 1.17% of the total share capital, with a total payment of RMB 91,674,284 (excluding transaction fees)[15] - The company has repurchased a total of 25,323,440 shares, with the highest transaction price at RMB 3.88 per share and the lowest at RMB 2.94 per share, totaling RMB 88,756,868 (excluding transaction fees)[17] - The company’s total share repurchase reached 24,823,440 shares, approximately 1.11% of the total share capital, with a total payment of RMB 86,881,868 (excluding transaction fees)[16] - The company’s stock repurchase plan allows for a maximum reduction of 22,263,945 shares, not exceeding 1% of the total share capital[17] Investment and Projects - The company plans to invest approximately RMB 489.36 million in the Hainan Dezheng International Medical and Health Complex project, with a total construction area of about 71,828 square meters and a construction period of 33 months[17] - The company’s subsidiary, Jialin Pharmaceutical, participated in the eighth national centralized procurement and is expected to win the bid for Amlodipine Atorvastatin Calcium Tablets[17] Research and Development - Research and development expenses for Q1 2023 were ¥11,907,421.27, an increase of 11.1% compared to ¥10,715,438.38 in Q1 2022[22] Financial Expenses - The company reported a financial expense of -¥19,002,480.13, compared to -¥13,068,207.92 in the previous year, indicating an increase in financial costs[24] Audit Status - The first quarter report was not audited[28]

证券代码： 000813 证券简称：天山纺织 编号：2014-09-25 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | | 上海证券报：樊英利、刘宏鹏、郑培源、徐晶晶、周鲁； | | 人员姓名 | | 西南证券：柯靓、於铀强、张煦。 | | 时间 | 2014 年 9 月 25 | 日上午 10： 30-12:30 点 | | 地点 | 公司 3 楼会议室 | | | 上市公司接待人 | | 董事长：武宪章；总经理：王广斌；副总经理：余熊来；副 | | 员姓名 | | 总经理、董秘：魏哲明；证券事务代表：蒋欣 ...

证券代码： 000813 证券简称：天山纺织 编号：2015-04-03 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-06-27 | --- | --- | --- | --- | |--------------------|-----------------------------------|----------------------------------------------|-------| | | | | | | | √ 特定对象调研 □分析师会议 | | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ 其他 （请文字说明其他活动内容） | | | | | 安信证券：崔文亮、孔令岩、肖寒 | | | | | | 中信证券资管：吴晓雯、于聪 国寿安保：刘志军 | | | | | 囯信证券：江维娜、徐巍 华商基金：张晓 华夏基 | | | 参与单位名称及人员 | 金：杨杨 嘉实基金：高兰君 | | | | | | 九州证券：岳志强 神农投资：殷南秋 | | | 姓名 | | 农银人寿：冯安铭、周建 ...

证券代码： 000813 证券简称：天山纺织 编号：2016-09-08 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | 西南证券：周平 | | | 人员姓名 | 建信养老基金：蒋锦 | | | | 东兴证券：胡偌碧 | | | | | 信达证券：单丹、张华、钟惠、胡申、李惜浣 | | | 新华汇嘉：戴泽龙 | | | | 中邮基金：陈梁 | | | | 中银基金：梦圆 | | | | 天风证券：廖庆阳 | | | | 建信基金：陈洁馨 | | | | 新华基金：潮礼君 | | | | 东方证券：季序我 | | | | 天弘基金：刘 ...